Antitumor Vaccination with Synthetic mRNA

Mainz, July 17, 2013 – Synthetic antigen-encoding mRNA is increasingly exploited as a tool for antigen-specific vaccination against cancer.
mRNA-based immunotherapies have proven to be feasible and safe and were able to elicit antigen-specific immune responses. The design of novel synthetic vaccines employing synthetic mRNA requires further in-depth investigation of its bioavailability and immune pharmacology.

Mustafa Diken, co-director of the TRON Immunotherapy Development Center and his colleagues have summarized the state-of-art in this field and described in vitro and in vivo methods elementary for preclinical studies of mRNA-based antitumor vaccine protocols. The article appeared in in Methods in Molecular Biology by Peter M. Rabinovich (ed.).